|
Numbers of cases aged 0–14 years, age-standardized rates (per million population) and 95% CIs, average annual percentage rate changes and 95% CIs, by diagnosis, sex and time period and test for sex-difference in temporal trend (P-value) |
|||||||||
| 1968–1980 |
1981–1993 |
1994–2005 |
% Ann. Inc |
M/F diff |
|||||
|
|
|||||||||
| CNS tumours |
Male |
134 |
28.5 (23.6,33.4) |
115 |
29.9 (24.4,35.4) |
133 |
38.4 (31.8,45.0) |
1.5 (0.5,2.5) |
0.74 |
| Female |
116 |
26.2 (21.3,31.0) |
91 |
25.1 (19.9,30.3) |
102 |
32.7 (26.3,39.2) |
1.2 (0.2,2.2) |
||
| Ependymomas |
Male |
18 |
4.3 (2.5,6.8) |
17 |
4.7 (2.7,7.5) |
16 |
4.9 (2.8,8.0) |
0.7 (-1.7,3.2) |
0.61 |
| Female |
10 |
2.4 (1.2,4.5) |
6 |
1.6 (0.6,3.5) |
5 |
1.9 (0.6,4.5) |
-0.5 (-4.6,3.6) |
||
| Astrocytomas |
Male |
38 |
7.9 (5.4,10.5) |
44 |
11.1 (7.8,14.4) |
55 |
15.5 (11.3,19.6) |
3.1 (1.7,4.6) |
0.33 |
| Female |
36 |
8.1 (5.4,10.8) |
29 |
7.9 (5.3,11.4) |
61 |
19.5 (14.5,24.5) |
4.4 (2.3,6.6) |
||
| PNET |
Male |
35 |
7.5 (4.9,10.0) |
16 |
4.4 (2.5,7.2) |
27 |
8.1 (5.3,11.8) |
0.6 (-1.6,2.9) |
0.86 |
| Female |
16 |
3.8 (2.1,6.1) |
15 |
4.3 (2.4,7.1) |
14 |
4.7 (2.5,7.8) |
0.9 (-1.7,3.6) |
||
| Other gliomas |
Male |
13 |
2.9 (1.5,5.0) |
10 |
2.6 (1.2,4.7) |
11 |
3.1 (1.5,5.6) |
0.7 (-2.4,3.9) |
0.42 |
| Female |
15 |
3.4 (1.9,5.6) |
9 |
2.6 (1.2,4.9) |
10 |
2.9 (1.4,5.4) |
-1.0 (-3.7,1.7) |
||
| Sympathetic nervous system tumours |
Male |
32 |
7.4 (4.8,10.0) |
43 |
12.6 (8.9,16.4) |
27 |
9.6 (6.3,14.0) |
0.9 (-0.5,2.4) |
0.29 |
| Female |
25 |
6.9 (4.5,10.2) |
34 |
10.3 (6.8,13.8) |
36 |
13.3 (8.9,17.6) |
2.2 (0.4,3.9) |
||
| Retinoblastoma |
Male |
16 |
4.2 (2.4,6.8) |
12 |
3.6 (1.9,6.3) |
10 |
3.6 (1.7,6.6) |
-0.3 (-3.6,3.1) |
0.42 |
| Female |
26 |
7.2 (4.7,10.5) |
17 |
5.4 (3.1,8.6) |
7 |
2.7 (1.1,5.6) |
-2.1 (-5.0,0.8) |
||
| Renal tumours |
Male |
28 |
6.8 (4.5,9.9) |
18 |
5.1 (3.0,8.0) |
25 |
9.0 (5.8,13.3) |
0.5 (-1.5,2.6) |
0.86 |
| Female |
31 |
8.3 (5.3,11.2) |
29 |
8.8 (5.9,12.7) |
25 |
9.4 (6.1,13.9) |
0.3 (-1.5,2.1) |
||
| Hepatoblastomas |
Male |
1 |
0.3 (0.0,1.5) |
1 |
0.3 (0.0,1.7) |
5 |
1.9 (0.6,4.4) |
7.3 (-0.2,14.9) |
0.18 |
| Female |
5 |
1.3 (0.4,3.0) |
2 |
0.6 (0.1,2.3) |
3 |
1.2 (0.2,3.4) |
0.5 (-5.5,6.6) |
||
| Bone tumours |
Male |
30 |
5.3 (3.4,7.2) |
17 |
4.0 (2.3,6.4) |
18 |
4.6 (2.7,7.3) |
0.3 (-2.1,2.7) |
0.58 |
| Female |
21 |
4.1 (2.5,6.3) |
21 |
5.1 (3.1,7.8) |
14 |
3.8 (2.1,6.4) |
-0.7 (-3.3,1.9) |
||
| Osteosarcoma |
Male |
18 |
3.1 (1.9,5.0) |
8 |
1.9 (0.8,3.8) |
8 |
2.0 (0.9,3.9) |
-0.9 (-4.3,2.6) |
0.80 |
| Female |
16 |
3.1 (1.8,5.1) |
12 |
2.9 (1.5,5.0) |
9 |
2.5 (1.1,4.7) |
-1.5 (-4.2,1.3) |
||
| Ewing's sarcoma |
Male |
12 |
2.2 (1.1,3.8) |
9 |
2.0 (0.9,3.9) |
8 |
2.0 (0.9,4.0) |
0.3 (-2.4,3.0) |
0.94 |
| Female |
4 |
0.8 (0.2,2.2) |
9 |
2.2 (1.0,4.2) |
3 |
0.8 (0.2,2.4) |
0.1 (-4.9,5.1) |
||
| Soft tissue sarcomas |
Male |
45 |
9.6 (6.7,12.4) |
46 |
12.5 (8.9,16.2) |
36 |
11.2 (7.5,14.9) |
1.3 (-0.2,2.8) |
0.70 |
| Female |
28 |
6.0 (4.0,8.7) |
22 |
5.8 (3.6,8.8) |
22 |
7.0 (4.4,10.7) |
0.8 (-1.2,2.9) |
||
| Rhabdomyosarcoma |
Male |
24 |
5.4 (3.4,8.1) |
26 |
7.2 (4.7,10.6) |
25 |
8.3 (5.3,12.3) |
2.4 (0.2,4.5) |
0.09 |
| Female |
19 |
4.3 (2.5,6.7) |
10 |
2.7 (1.3,5.1) |
10 |
3.7 (1.7,6.7) |
-0.4 (-2.7,1.9) |
||
| Other |
Male |
21 |
4.2 (2.6,6.4) |
20 |
5.3 (3.2,8.2) |
11 |
2.9 (1.4,5.2) |
-0.4 (-2.9,2.1) |
0.19 |
| Female |
9 |
1.7 (0.8,3.3) |
12 |
3.1 (1.6,5.4) |
12 |
3.4 (1.7,5.9) |
2.5 (-1.1,6.0) |
||
| Germ cell tumours |
Male |
17 |
4.4 (2.5,7.0) |
18 |
5.1 (3.0,8.1) |
20 |
6.5 (4.0,10.2) |
2.1 (-0.7,4.8) |
0.02 |
| Female |
8 |
1.8 (0.7,3.5) |
20 |
5.7 (3.5,8.9) |
32 |
10.6 (6.9,14.4) |
6.2 (4.1,8.3) |
||
| Gonadal |
Male |
13 |
3.4 (1.8,5.8) |
13 |
3.9 (2.1,6.6) |
6 |
2.1 (0.8,4.6) |
-1.1 (-4.9,2.7) |
0.001 |
| Female |
2 |
0.4 (0.0,1.3) |
2 |
0.5 (0.1,1.8) |
14 |
4.0 (2.1,6.7) |
8.6 (4.3,12.9) |
||
| Non-gonadal |
Male |
4 |
1.0 (0.3,2.5) |
5 |
1.2 (0.4,2.9) |
14 |
4.4 (2.4,7.5) |
7.2 (2.6,11.8) |
0.50 |
| Female |
6 |
1.4 (0.5,3.1) |
18 |
5.2 (3.1,8.3) |
18 |
6.6 (3.9,10.5) |
5.4 (2.8,7.9) |
||
| Carcinomas |
Male |
11 |
2.0 (1.0,3.7) |
13 |
3.0 (1.6,5.1) |
15 |
4.2 (2.3,6.9) |
3.2 (0.1,6.3) |
0.31 |
| Female |
17 |
3.8 (2.2,6.1) |
20 |
5.0 (3.0,7.7) |
17 |
5.0 (2.9,8.0) |
1.1 (-1.5,3.7) |
||
| Thyroid |
Male |
2 |
0.4 (0.0,1.3) |
2 |
0.5 (0.1,1.7) |
5 |
1.3 (0.4,3.0) |
5.9 (-0.4,12.2) |
0.07 |
| Female |
4 |
0.9 (0.2,2.4) |
3 |
0.7 (0.1,2.0) |
2 |
0.6 (0.1,2.0) |
-1.8 (-7.1,3.4) |
||
| Melanoma |
Male |
2 |
0.3 (0.0,1.2) |
3 |
0.7 (0.1,2.0) |
2 |
0.6 (0.1,2.3) |
4.3 (-2.8,11.4) |
0.81 |
| Female |
3 |
0.7 (0.1,2.2) |
8 |
2.1 (0.9,4.1) |
5 |
1.6 (0.5,3.7) |
3.1 (-2.7,9.0) |
||
| Skin |
Male |
0 |
- |
2 |
0.4 (0.1,1.5) |
2 |
0.5 (0.1,1.9) |
9.6 (0.0,19.2) |
0.46 |
| Female |
0 |
- |
2 |
0.5 (0.1,1.6) |
2 |
0.5 (0.1,1.8) |
4.5 (-4.8,13.8) |
||
| Breast |
Male |
0 |
- |
0 |
- |
0 |
- |
- |
- |
| Female |
0 |
- |
0 |
- |
0 |
- |
- |
||
| Genital/other reproductive |
Male |
0 |
- |
0 |
- |
0 |
- |
- |
- |
| Female |
0 |
- |
1 |
0.3 (0.0,1.8) |
0 |
- |
2.9 (-15.1,20.9) |
||
| Lung and bronchial |
Male |
1 |
0.2 (0.0,1.1) |
0 |
- |
0 |
- |
-12.1 (-25.9,1.6) |
0.12 |
| Female |
1 |
0.2 (0.0,1.0) |
0 |
- |
1 |
0.3 (0.0,1.4) |
2.8 (-9.6,15.2) |
||
| Colorectal |
Male |
0 |
- |
0 |
- |
0 |
- |
- |
- |
| Female |
1 |
0.2 (0.0,1.0) |
0 |
- |
1 |
0.3 (0.0,1.4) |
2.5 (-9.9,14.8) |
||
|
|
|||||||||
| TOTAL |
Male |
314 |
68.6 (60.8,76.3) |
283 |
76.1 (67.1,85.0) |
289 |
89.0 (78.6,99.4) |
1.3 (0.7,1.9) |
0.84 |
| Female |
277 |
65.4 (57.6,73.2) |
256 |
71.8 (62.9,80.7) |
258 |
85.7 (75.0,96.3) |
1.2 (0.5,2.0) |
||
|
Figures are counts, ASRs with 95% CIs, Annual Percentage Change in ASR with 95% CIs (estimated from linear regression model) and p value for testing M/F difference in trend (obtained from year *sex interaction term in linear regression model) | |||||||||
Magnanti et al. BMC Cancer 2008 8:89 doi:10.1186/1471-2407-8-89 |
|||||||||